TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03244319
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
Study: NCT03244319
Drug: parenteral anti-coagulant (UFH)
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parenteral anti-coagulant (UFH)
Study: NCT02822131
Drug: sevelamer, sodium bicarbonate, sodium chloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00363779
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
Study: NCT02770807
Drug: EryDex Low dose DSP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EDS-EP dose range of \~5-10 mg DSP/infusion
Study: NCT01289223
Drug: Bendamustine IV
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00711802
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02370095
Drug: Treprostinil Inhalation Solution
Normalized name: Treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treprostinil inhalation solution administered as blinded marketed product
Study: NCT00900146
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Study: NCT00900146
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
Study: NCT00276094
Drug: Ospemifene 30 mg
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Study: NCT00276094
Drug: Ospemifene 60 mg
Normalized name: ospemifene 60 MG
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Study: NCT00276094
Drug: Nonhormonal vaginal lubricant
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
Study: NCT00378937
Drug: morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00378937
Drug: oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02770807
Drug: EryDex High dose DSP
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS-EP dose range of \~14-22 mg DSP/infusion
Study: NCT02046850
Drug: selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
Study: NCT02046850
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
Study: NCT02046850
Drug: selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
Study: NCT02046850
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
Study: NCT00701636
Drug: daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
Study: NCT00146185
Drug: ALGRX 3268
Normalized name: ALGRX 1207
DrugBank: ALGRX 1207 (DB06482)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00526110
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.2 Gm/m\^2 IV over 48 hours on Day 1.
Study: NCT00526110
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m\^2 IV over 60 minutes
Study: NCT00526110
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m\^2 IV over 120 minutes on Day 1.
Study: NCT01011933
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03077698
Drug: Sodium Cridanimod
Normalized name: cridanimod
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
Study: NCT03250039
Drug: PF-04965842
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 14C labeled PF-04965842
Study: NCT03250039
Drug: Absolute Bioavailability
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
Study: NCT00000504
Drug: encainide
Normalized name: Encainide
DrugBank: Encainide (DB01228)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000504
Drug: moricizine
Normalized name: Moricizine
DrugBank: Moricizine (DB00680)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000504
Drug: flecainide
Normalized name: Flecainide
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000504
Drug: imipramine
Normalized name: Imipramine
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03094286
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
Study: NCT03947528
Drug: Sarpogrelate HCL 300mg
Normalized name: amiodarone hydrochloride 300 MG
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose administration in healthy volunteers under fed condition
Study: NCT01605487
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
Study: NCT01605487
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
Study: NCT01605487
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
Study: NCT01605487
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
Study: NCT01605487
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
Study: NCT01605487
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
Study: NCT04140201
Drug: Fenofibrate 200mg
Normalized name: FENOFIBRATE 200MG CAP
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs that lower lipid levels
Study: NCT04140201
Drug: Omega 3 fatty acid
Normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs that lower lipid levels
Study: NCT02523768
Drug: ATG-F
Normalized name: ATG-Fresenius S
DrugBank: ATG-Fresenius S (DB05320)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02523768
Drug: Simulect
Normalized name: Simulect
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05562362
Drug: RE-021, sparsentan
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
Study: NCT01239888
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
Study: NCT01239888
Drug: Oxytocin and Tibolone
Normalized name: TIBOLONE
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
Study: NCT01969617
Drug: Nalmefene 18 mg, then placebo
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One single oral dose Nalmefene on Day 1 and Placebo on Day 8
Study: NCT01969617
Drug: Placebo, then Nalmefene 18 mg
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One single oral dose Placebo on Day 1 and Nalmefene on Day 8
Study: NCT01223898
Drug: Tasigna
Normalized name: Tasigna
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03230812
Drug: Carnitene (L-Carnitine or Levocarnitine)
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
Study: NCT03790358
Drug: Lysergic Acid Diethylamide
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be administered in solution form.
Study: NCT03843944
Drug: Safinamide
Normalized name: Safinamide
DrugBank: Safinamide (DB06654)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
Study: NCT02146703
Drug: Gemcitabine, and S-1
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14
Study: NCT02036736
Drug: Intraoperative anesthetic strategy by Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade
Study: NCT02036736
Drug: Intraoperative anesthetic strategy by Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade
Study: NCT01366612
Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1
Study: NCT01366612
Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1
Study: NCT00099060
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~* Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~* Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events.
Study: NCT04021524
Drug: Benzoyl Peroxide 10% Bar
Normalized name: BENZOYL PEROXIDE 10% BAR
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will wash with Benzoyl Peroxide 10% Bar
Study: NCT04021524
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will wash with Chlorhexidine Gluconate
Study: NCT01921218
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
Study: NCT01921218
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
Study: NCT01921218
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
Study: NCT03172065
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anaesthetic adjuvants and pain killer medication.
Study: NCT02180880
Drug: Pregabalin and Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.
Study: NCT00016367
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1.
Study: NCT00016367
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.
Study: NCT03198689
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
Study: NCT00906139
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol dose: 0.5 mg/kg up to 400 mg
Study: NCT00906139
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam dose: 0.1 mg/kg
Study: NCT00354107
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00354107
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00354107
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00354107
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT04035564
Drug: Sodium < 1mEq/kg/day
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
Study: NCT04035564
Drug: Sodium 5mEq/kg/day
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
Study: NCT02267304
Drug: 50 mL of sodium chloride (0,9%)
Normalized name: sodium chloride 50 MG/ML
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02267304
Drug: Morphine 0,05mg/kg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02267304
Drug: Naloxone 10mg
Normalized name: NALOXONE 10MG/0.4ML AUTOINJECTOR,KIT
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00106600
Drug: Pixantrone IV infusion
DrugBank: Pixantrone (DB06193)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00892203
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01678352
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cohort 1 Cohort 2 Cohort 3
Study: NCT01838785
Drug: 18F-DTBZ AV-133
Normalized name: 18F-AV-133
DrugBank: Florbenazine F-18 (DB14945)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03529097
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 liters of 0.9% NaCl IV fluids
Study: NCT03529097
Drug: Optalgin, Voltaren, Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
Study: NCT00031980
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04690920
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
Study: NCT03887065
Drug: JM-4
Normalized name: JM
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel small human peptide derived from erythropoietin
Study: NCT00823212
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Study: NCT00823212
Drug: Thienopyridine
Normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study: NCT02486042
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).